Search results for "Retrospective Cohort Study"

showing 10 items of 1452 documents

No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML

2017

Objective:To examine retrospectively the effects of plasmapheresis (PLEX) on the survival and clinical outcomes of patients with multiple sclerosis (MS) and natalizumab (NTZ)–associated progressive multifocal leukoencephalopathy (PML).Methods:The medical literature was searched for the terms natalizumab and progressive multifocal leukoencephalopathy. A total of 193 international and 34 Italian NTZ-PML cases were included. Clinical outcome was determined by comparing the patients' clinical status at PML diagnosis with status after PML resolution. The effects on survival and clinical outcome of PLEX, sex, age, country, pre-PML Expanded Disability Status Scale score, NTZ infusion number, prior…

OncologyMaleJC virus030204 cardiovascular system & hematologymedicine.disease_causeLeukoencephalopathyDisability Evaluationneurology (clinical); progressive multifocal leukoencephalopathy; reconstitution inflammatory syndrome; multiple-sclerosis0302 clinical medicineNatalizumabImmunologic FactorLeukoencephalopathyRetrospective StudieMultiple SclerosiMedicinePlasmapheresiAdult; Disability Evaluation; Female; Humans; Immunologic Factors; Leukoencephalopathy Progressive Multifocal; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Plasmapheresis; PubMed; Retrospective Studies; Statistics Nonparametric; Treatment OutcomeProgressive multifocal leukoencephalopathyNatalizumabStatisticsLeukoencephalopathy Progressive MultifocalPlasmapheresisMiddle AgedTreatment OutcomeFemaleSettore MED/26 - Neurologiamedicine.drugHumanAdultmedicine.medical_specialtyPubMedMultiple SclerosisProgressive MultifocalStatistics Nonparametric03 medical and health sciencesImmune reconstitution inflammatory syndromeInternal medicineHumansImmunologic FactorsNonparametricprogressive multifocal leukoencephalopathy multiple sclerosis side effectRetrospective StudiesExpanded Disability Status Scalebusiness.industryMultiple sclerosisRetrospective cohort studymedicine.diseaseImmunologyNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients

2012

PML regulates a wide range of pathways involved in tumorigenesis, such as apoptosis, which is also one of the main mechanisms through which oxaliplatin and fluoropyrimidine exert their antineoplastic activity. The present study aims to investigate PML expression as a predictive factor of oxaliplatin/fluoropyrimidine therapy efficacy. Seventy-four metastatic colorectal cancer patients who received oxaliplatin/floropyrimidine-based first line therapy have been included in this retrospective study. PML expression was assessed by immunohistochemistry. PML down-regulation was detected in 39 (52.7%) patients (14 complete and 25 partial PML loss). RR was significantly lower (25.6%) in patients wit…

OncologyMaleOrganoplatinum CompoundsOxaloacetatesPhysiologyColorectal cancerSettore MED/06 - Oncologia MedicavirusesClinical BiochemistryCellLeucovorinPromyelocytic Leukemia Proteinmedicine.disease_causeDeoxycytidineAntineoplastic Combined Chemotherapy Protocolsbiologyvirus diseasesNuclear ProteinsMiddle AgedOxaliplatinSurvival Ratemedicine.anatomical_structureImmunohistochemistryoxaliplatin/fluoropyrimidineFemaleFluorouracilColorectal Neoplasmsmedicine.drugAdultmedicine.medical_specialtyAntimetabolites AntineoplasticPML; oxaliplatin/fluoropyrimidine; colorectal cancerAntineoplastic Agentscolorectal cancerPromyelocytic leukemia proteinPredictive Value of TestsInternal medicinemedicineHumansCapecitabineAgedRetrospective StudiesPMLbusiness.industryTumor Suppressor ProteinsRetrospective cohort studyCell Biologymedicine.diseaseOxaliplatinApoptosisDrug Resistance Neoplasmbiology.proteinCarcinogenesisbusinessTranscription Factors
researchProduct

Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma

2016

Background Prognostic assessment in patients with hepatocellular carcinoma (HCC) remains controversial. Using the Italian Liver Cancer (ITA.LI.CA) database as a training set, we sought to develop and validate a new prognostic system for patients with HCC. Methods and Findings Prospective collected databases from Italy (training cohort, n = 3,628; internal validation cohort, n = 1,555) and Taiwan (external validation cohort, n = 2,651) were used to develop the ITA.LI.CA prognostic system. We first defined ITA.LI.CA stages (0, A, B1, B2, B3, C) using only tumor characteristics (largest tumor diameter, number of nodules, intra- and extrahepatic macroscopic vascular invasion, extrahepatic metas…

OncologyMaleTime FactorsDatabases FactualCancer Treatmentlcsh:MedicinePredictive Value of TestPediatricsBiochemistryGeographical locationsNeoplasms Multiple PrimaryDecision Support Technique0302 clinical medicineInterquartile rangeRetrospective StudieMultiple PrimaryRisk FactorsNeoplasmsMedicine and Health SciencesEthnicitiesPublic and Occupational HealthLiver DiseasesLiver NeoplasmsChild HealthGeneral MedicineMiddle AgedPrognosisItalian PeopleTumor BurdenQuartileOncologyCirrhosisItalyLiver Neoplasm030220 oncology & carcinogenesisPredictive value of testsCohortPerspectiveHong Kong030211 gastroenterology & hepatologyFemaleSurvival Analysialpha-FetoproteinsHumanBiotechnologymedicine.medical_specialtyCarcinoma HepatocellularAsiaTime FactorSettore MED/12 - GASTROENTEROLOGIAAged; Carcinoma Hepatocellular; Databases Factual; Decision Support Techniques; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms Multiple Primary; Predictive Value of Tests; Reproducibility of Results; Retrospective Studies; Risk Assessment; Risk Factors; Survival Analysis; Taiwan; Time Factors; Tumor Burden; alpha-Fetoproteins; Biotechnology; Biochemistry; Molecular Biology; Cell BiologyTaiwanReproducibility of ResultGastroenterology and HepatologyCarcinomasRisk AssessmentDecision Support Techniques03 medical and health sciencesDatabasesDiagnostic MedicinePredictive Value of TestsInternal medicineGastrointestinal TumorsmedicineHumansNeoplasm Invasivenessalpha-FetoproteinMolecular BiologySurvival analysisFactualAgedNeoplasm StagingRetrospective StudiesNeoplasm InvasivenePerformance statusbusiness.industryRisk Factorlcsh:RCarcinomaCancers and NeoplasmsReproducibility of ResultsRetrospective cohort studyHepatocellularHepatocellular CarcinomaCell BiologySurvival AnalysisBCLC StageSurgeryPeople and PlacesPopulation Groupingsbusiness
researchProduct

Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fet…

2015

The lifetime utility of liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) is still controversial. The aim of this study was to ascertain when LT is cost-effective for HCC patients, with a view to proposing new transplant selection criteria. The study involved a real cohort of potentially transplantable Italian HCC patients (n = 2419 selected from the Italian Liver Cancer group database) who received nontransplant therapies. A non-LT survival analysis was conducted, the direct costs of therapies were calculated, and a Markov model was used to compute the cost utility of LT over non-LT therapies in Italian and US cost scenarios. Post-LT survival was calculated using t…

OncologyMaleTime FactorsDatabases Factualmedicine.medical_treatmentCost-Benefit AnalysisLiver transplantationClinical endpointLiver NeoplasmsSurgery; Transplantation; HepatologyHealth Care Costshepatocellular carcinomaMiddle AgedMarkov ChainsTumor BurdenModels EconomicTreatment OutcomeItalyHepatocellular carcinomaFemaleQuality-Adjusted Life Yearsalpha-FetoproteinsAlpha-fetoproteinMonte Carlo Methodmedicine.medical_specialtyCarcinoma HepatocellularSettore MED/12 - GASTROENTEROLOGIADecision Support Techniquesalpha-fetoproteinPredictive Value of TestsInternal medicinemedicineHumansneoplasmsSurvival analysisAgedProportional Hazards ModelsRetrospective StudiesTransplantationHepatologyProportional hazards modelbusiness.industryPatient SelectionRetrospective cohort studymedicine.diseaseSurvival Analysisdigestive system diseasesUnited StatesSurgeryLiver TransplantationTransplantationMultivariate AnalysisSurgerybusiness
researchProduct

Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective …

2017

Abstract Introduction:Even in the era of novel targeted therapies for the treatment of Chronic Lymphocytic Leukemia (CLL) patients, such as BTK, PI3K and BCL2 inhibitors, allogeneic hematopoietic stem cell transplantations (alloHCT) will remain an important treatment option for a subset of patients with very high risk CLL. The current study focused on the impact of center and procedure-related factors on outcomes after alloHCT, taking into account the impact of patient- and disease-related risk factors. Patients and Methods:Data of 684 CLL patients who received a first alloHCT between 2000 and 2011 were analyzed. Their data were collected as part of the EBMT CLL Data Quality Initiative. Out…

OncologyMaleTransplantation ConditioningCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Chronic lymphocytic leukemiaMedizinQUALITY MANAGEMENT-SYSTEMKaplan-Meier Estimaterisk factor analysisGUIDELINESBiochemistryallogeneic stem cell transplantation; centre effects; chronic lymphocytic leukaemia; frailties; risk factor analysiscentre effectsTransplantation Conditioning / methods0302 clinical medicineRecurrenceRisk Factorsallogeneic stem cell transplantationLeukemia Lymphocytic Chronic B-Cell / mortalityRegistriesDelivery of Health Care / statistics & numerical dataIBRUTINIBddc:6160303 health sciencesALEMTUZUMABHazard ratioHematopoietic Stem Cell TransplantationProfessional PracticeHematologyMiddle Aged3. Good healthEurope030220 oncology & carcinogenesisABT-199CohortSURVIVALAlemtuzumabFemaleEurope / epidemiologymedicine.drugAdultmedicine.medical_specialtyAllogeneic transplantationImmunologyLower riskDIAGNOSISSettore MED/01 - Statistica Medica03 medical and health sciencesLeukemia Lymphocytic Chronic B-Cell / therapyHematopoietic Stem Cell Transplantation / methodsInternal medicinemedicineHumansKarnofsky Performance Status030304 developmental biologyAgedRetrospective Studiesbusiness.industryProportional hazards modelCHRONIC LYMPHOCYTIC-LEUKEMIARetrospective cohort studySTEM-CELL TRANSPLANTATIONCell Biologymedicine.diseaseLeukemia Lymphocytic Chronic B-CellConfidence intervalSurgeryProfessional Practice / statistics & numerical dataTransplantationbusinessDelivery of Health Carefrailtieschronic lymphocytic leukaemia030215 immunologyRESPONSES
researchProduct

Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study

2021

Not Available

OncologyMalechronic B cell leukemiachronic lymphocytic leukemia; ibrutinib; 4-factor score; prognosis.Datasets as TopicSeverity of Illness Indexchemistry.chemical_compoundPiperidinesRetrospective analysisMulticenter Studies as TopicChronicLeukemiaHematologyMiddle AgedPrognosisLymphocyticProgression-Free SurvivalIbrutinibFemalemedicine.medical_specialtyreal-word studyFactor scoreAntineoplastic AgentsAdenine; Aged; Antineoplastic Agents; Datasets as Topic; Female; Follow-Up Studies; Humans; Leukemia Lymphocytic Chronic B-Cell; Male; Middle Aged; Multicenter Studies as Topic; Piperidines; Prognosis; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Reproducibility of Results; Retrospective Studies; Risk Assessment; Severity of Illness Index; Survival AnalysisRisk AssessmentNOibrutinibInternal medicineSeverity of illnessmedicineHumansProgression-free survivalProtein Kinase InhibitorsSurvival analysisAgedProportional Hazards ModelsRetrospective Studiesbusiness.industryProportional hazards modelAdenineB-CellReproducibility of ResultsRetrospective cohort studyAdenine; Aged; Antineoplastic Agents; Datasets as Topic; Female; Follow-Up Studies; Humans; Leukemia Lymphocytic Chronic B-Cell; Male; Middle Aged; Multicenter Studies as Topic; Piperidines; Prognosis; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Reproducibility of Results; Retrospective Studies; Risk Assessment; Survival Analysis; Severity of Illness IndexLeukemia Lymphocytic Chronic B-CellSurvival AnalysisSettore MED/15 - MALATTIE DEL SANGUEchemistrybusinesschronic lymphocytic leukaemiaFollow-Up Studies
researchProduct

Tweet this: how advocacy for breast and prostate cancers stacks up on social media.

2017

OncologyMalemedicine.medical_specialty020205 medical informaticsDatabases FactualUrologyMEDLINEBreast Neoplasms02 engineering and technology03 medical and health sciences0302 clinical medicineProstateInternal medicine0202 electrical engineering electronic engineering information engineeringmedicineHumansSocial media030212 general & internal medicineRetrospective Studiesbusiness.industryInformation DisseminationIncidence (epidemiology)IncidenceProstatic NeoplasmsRetrospective cohort studyUnited Kingdommedicine.anatomical_structureFamily medicineFemalebusinessSocial MediaBJU international
researchProduct

Expanding the Liver Imaging Reporting and Data System (LI-RADS) v2018 diagnostic population: performance and reliability of LI-RADS for distinguishin…

2018

Abstract Background Hepatocellular carcinoma (HCC) can be diagnosed using imaging criteria in patients at high-risk for HCC, according to Liver Imaging Reporting and Data System (LI-RADS) guidelines. The aim of this study was to determine the diagnostic performance and inter-rater reliability (IRR) of LI-RADS v2018 for differentiating HCC from non-HCC primary liver carcinoma (PLC), in patients who are at increased risk for HCC but not included in the LI-RADS ‘high-risk’ population. Methods This retrospective HIPAA-compliant study included a 10-year experience of pathologically-proven PLC at two liver transplant centers, and included patients with non-cirrhotic hepatitis C infection, non-cir…

OncologyMalemedicine.medical_specialtyCarcinoma HepatocellularPopulationSensitivity and SpecificityCholangiocarcinoma03 medical and health sciences0302 clinical medicineInternal medicineCarcinomaMedicineData SystemsHumanseducationneoplasmsAgedRetrospective Studieseducation.field_of_studyLI-RADS Hepatocellular carcinomaHepatologymedicine.diagnostic_testbusiness.industryFatty liverLiver NeoplasmsGastroenterologyReproducibility of ResultsMagnetic resonance imagingRetrospective cohort studyHepatitis CHepatitis C Chronicmedicine.diseaseMagnetic Resonance Imagingdigestive system diseasesFatty Liver030220 oncology & carcinogenesisHepatocellular carcinomaCohort030211 gastroenterology & hepatologyFemalebusinessTomography X-Ray ComputedSettore MED/36 - Diagnostica Per Immagini E Radioterapia
researchProduct

The Fuhrman grading system has no prognostic value in patients with nonsarcomatoid chromophobe renal cell carcinoma.

2014

The prognostic value of the Fuhrman nuclear grading system has been questioned for chromophobe renal cell carcinoma (chRCC) because this subtype frequently displays nuclear and nucleolar pleomorphism. The present study reevaluates this grading system in a series of patients with nonsarcomatoid chRCC. We identified 176 patients (3.6%) with nonsarcomatoid chRCC in a total of 4897 patients who underwent surgery for renal cell carcinoma at 5 centers in Germany between 1990 and 2010. The mean follow-up was 51.1 months. The 3 groups (G1 versus G2 versus G3/4) were comparable in terms of age, sex, tumor diameter, and lymph node metastasis. They only differed significantly in tumor stage (P = .01) …

OncologyMalemedicine.medical_specialtyChromophobe Renal Cell CarcinomaUrologyPathology and Forensic MedicineRenal cell carcinomaInternal medicineMedicineHumansSurvival rateCarcinoma Renal CellRetrospective StudiesNeoplasm Gradingbusiness.industryHistologyRetrospective cohort studyMiddle Agedmedicine.diseasePrognosisKidney NeoplasmsSurvival RatePleomorphism (cytology)Lymphatic MetastasisCohortFemaleNeoplasm GradingbusinessHuman pathology
researchProduct

Prognostic significance of tumor ploidy and histomorphological parameters in adenocarcinoma of Barrett's esophagus.

1999

<i>Background:</i> Despite recent advances in surgical and multidisciplinary treatment, the prognosis for patients with adenocarcinoma of Barrett’s esophagus remains poor. The low prognostic accuracy of even surgical pathologic TNM staging suggests that additonal parameters are necessary in determining the prognosis. <i>Method:</i> In a retrospective analysis of 50 patients who underwent transhiatal or transthoracic esophageal resection due to adenocarcinoma of Barrett’s esophagus, a quantitative DNA analysis using image cytometry was performed in addition to the TNM classification and usual morphological criteria. At the time of DNA analysis the histomorphological p…

OncologyMalemedicine.medical_specialtyEsophageal NeoplasmsAdenocarcinomaGastroenterologyBarrett EsophagusEsophagusInternal medicinemedicineHumansEsophagusDna ploidyImage CytometryProportional Hazards ModelsRetrospective StudiesPloidiesProportional hazards modelbusiness.industryGastroenterologyRetrospective cohort studyDNA Neoplasmmedicine.diseasePrognosisdigestive system diseasesmedicine.anatomical_structureBarrett's esophagusAdenocarcinomaImage CytometrySurgeryFemalePloidybusinessDigestive surgery
researchProduct